SYM FINANCIAL Corp Acquires 50 Shares of West Pharmaceutical Services, Inc. $WST

SYM FINANCIAL Corp increased its holdings in shares of West Pharmaceutical Services, Inc. (NYSE:WST) by 5.1% in the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 1,027 shares of the medical instruments supplier’s stock after buying an additional 50 shares during the period. SYM FINANCIAL Corp’s holdings in West Pharmaceutical Services were worth $225,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also modified their holdings of WST. Bessemer Group Inc. increased its stake in West Pharmaceutical Services by 43.7% in the first quarter. Bessemer Group Inc. now owns 1,075 shares of the medical instruments supplier’s stock valued at $241,000 after purchasing an additional 327 shares in the last quarter. Robeco Institutional Asset Management B.V. increased its stake in West Pharmaceutical Services by 34.7% in the first quarter. Robeco Institutional Asset Management B.V. now owns 5,581 shares of the medical instruments supplier’s stock valued at $1,249,000 after purchasing an additional 1,437 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. boosted its holdings in shares of West Pharmaceutical Services by 17.4% in the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 12,784 shares of the medical instruments supplier’s stock valued at $2,841,000 after buying an additional 1,893 shares during the period. KBC Group NV boosted its holdings in shares of West Pharmaceutical Services by 6.3% in the first quarter. KBC Group NV now owns 10,612 shares of the medical instruments supplier’s stock valued at $2,376,000 after buying an additional 632 shares during the period. Finally, Amalgamated Bank boosted its holdings in shares of West Pharmaceutical Services by 1.0% in the first quarter. Amalgamated Bank now owns 14,749 shares of the medical instruments supplier’s stock valued at $3,302,000 after buying an additional 145 shares during the period. 93.90% of the stock is owned by institutional investors.

West Pharmaceutical Services Price Performance

NYSE:WST opened at $283.54 on Wednesday. The firm has a market cap of $20.40 billion, a price-to-earnings ratio of 42.01, a P/E/G ratio of 4.12 and a beta of 1.07. The company has a debt-to-equity ratio of 0.07, a quick ratio of 2.18 and a current ratio of 2.87. West Pharmaceutical Services, Inc. has a 52 week low of $187.43 and a 52 week high of $348.90. The firm’s 50-day simple moving average is $260.89 and its 200 day simple moving average is $235.79.

West Pharmaceutical Services (NYSE:WST) last posted its quarterly earnings results on Thursday, October 23rd. The medical instruments supplier reported $1.96 earnings per share for the quarter, beating analysts’ consensus estimates of $1.67 by $0.29. West Pharmaceutical Services had a net margin of 16.29% and a return on equity of 18.16%. The company had revenue of $804.60 million for the quarter, compared to the consensus estimate of $788.42 million. During the same period last year, the company posted $1.85 EPS. The firm’s quarterly revenue was up 7.7% compared to the same quarter last year. West Pharmaceutical Services has set its FY 2025 guidance at 7.060-7.110 EPS. As a group, sell-side analysts predict that West Pharmaceutical Services, Inc. will post 6.62 earnings per share for the current year.

Wall Street Analyst Weigh In

WST has been the subject of several recent research reports. Barclays increased their target price on shares of West Pharmaceutical Services from $275.00 to $325.00 and gave the stock an “equal weight” rating in a report on Monday. Rothschild & Co Redburn started coverage on shares of West Pharmaceutical Services in a research report on Monday, September 15th. They issued a “buy” rating and a $311.00 price objective on the stock. Redburn Partners set a $311.00 price objective on shares of West Pharmaceutical Services in a research report on Monday, September 15th. Evercore ISI increased their price objective on shares of West Pharmaceutical Services from $350.00 to $390.00 and gave the company an “outperform” rating in a research report on Thursday, October 23rd. Finally, Zacks Research lowered shares of West Pharmaceutical Services from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, September 23rd. Two investment analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $349.11.

About West Pharmaceutical Services

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.